MRFR Year End Sale
Monoclonal Antibody Therapy Market - Forecast To 2030

Monoclonal Antibody Therapy Market information, by source (recombinant, chimeric, humanized, human, and other), Application (diagnostic test, analytical and chemical uses, cancer treatment, autoimmune diseases, hematological disorders, and others), End users (hospitals, clinic, research laboratories and others) - Forecast to 2030

ID: MRFR/Pharma/1557-HCR | December 2022 | Region: Global | 80 Pages         

Monoclonal Antibody Therapy Market

The monoclonal antibody therapy market Is Projected To Reach USD 458.1 billion, Enlisting a CAGR of 12.8% By 2030


By source Human Murine Humanized Chimeric
By indication Infectious Diseases Breast cancer Inflammatory disease Colorectal cancer Autoimmune disease Lung cancer Ovarian cancer Lung cancer
By end-users Research institutions Hospitals

Key Players

  • Sigma-Aldrich Co. LLC
  • Sanofi
  • Pfizer Inc
  • Novartis AG
  • Merck Kae
  • Johnson & Johnson
  • GlaxoSmithKline Plc
  • GenScript
  • AbbVie Inc
  • Amgen Inc
  • Bayer AG


  • technological advancement
  • macro economical and governing factors
Speak to Analyst Request a Free Sample

Monoclonal Antibody Therapy Market Overview 

The monoclonal antibody therapy market size is expected to reach USD 458.1 billion at 12.8% CAGR during the forecast period 2022-2030. The monoclonal antibody is a type of immunotherapy therapy that uses mono antibodies to attach certain proteins. The monoclonal antibody is known as a cell that is a replica of identical immune cells. By combining these antibodies, it can create an antigen. Also, reaching the monovalent affinity is possible through this process. Monoclonal antibodies are exceptional tools to identify substances.

The wide range of applications will bring various monoclonal antibodies that are useful in various fields such as medicine, biochemistry and molecular biology. The laboratory-produced monoclonal is the best substitute for natural ones. Through these antibodies, attacking any cells in the immune system is possible. Through research and development many monoclonal antibodies are created in labs.

The demand for monoclonal products is massive in the medical sector. It can act as revolutionary medicine for many diseases. This cell is widely used in the treatment of cancer. Targeting cancer cells with the monoclonal antibody is possible through these procedures. The increasing demand for the product in cancer institute’s, research centres and hospitals are surging. All these factors will increase overall monoclonal antibody therapy market value in the upcoming years. 

Covid analysis 

The outbreak of covid 19 is causing much disturbance to the global monoclonal antibody therapy markets. This health emergency is causing an economic crisis globally. The monoclonal antibody therapy for covid 19 analysis shows that there are few disruptions due to this condition. However, this situation is expected to get better in upcoming years. Rising support from the government for the health industry will create positive changes. The investments of the government are increasing for cancer treatments.

However, there are some companies that are struggling to sustain themselves. This period is slowing down research in the monoclonal antibody therapy market. There are uncertain losses in the market that will lead to declining demand. The governmental support is except to enhance the monoclonal antibody therapy market growth. In the upcoming years, companions and the launch of several research facilities will happen. These factors will bring favourable changes in upcoming years. 

Market dynamics

  • Crucial market drivers 

The increase in chronic diseases is a crucial driver for the monoclonal antibody therapy market. The prevalence of cancer is leading to more adoption of monoclonal antibodies. These biosimilar antibodies are cost-efficient treatments available for cancer. Furthermore, Technological improvement drove the market demand. In recent years, the health industry is witnessing impressive technological developments. This leads to better treatments for necessary chronic diseases

As per the international medical journal, the ageing population is expected to increase in upcoming years. The number of cases is accepted to rise with the geriatric population. These factors will provide massive scope for monoclonal antibody therapy. There are new types of cancer cases in many regions. Different classes and types of cancers are detectable with high-end equipment. Also, the launch of genetic platforms makes it possible to carry to new monoclonal antibody procedures. In the upcoming years, the next-gene sequencing will lead to remarkable changes in the monoclonal antibody therapy market.

With next-gene sequencing, cost-efficient and effective treatment for cancer is available for patients. The technological advancement will increase the overall revenue rates of the monoclonal antibody therapy market in the forecast period. Furthermore, the rising awareness about antibody therapy will lead to more demand. Today, May hospitals and clinics are adapting to this therapy. Accessibility of such treatments is rising in developed regions. In the forecast period, all these drivers rise monoclonal antibody therapy market size. 

  • The market growth opportunities 

The growth of research will bring massive growth opportunities to the monoclonal antibody therapy market. The investments for the R&D of the monoclonal market are rising in upcoming years. It increases therapy techniques and mechanisms will see development. There are massive chances for new drug launches in the market. The monoclonal antibodies segment is combined with chemical payloads will have high demand. This combination leads to effective immunotherapy arsenal diseases for chronic illnesses and cancer. These developments will attract end-users towards monoclonal antibody therapy. 

Due to high research, the pharmaceutical segment of the market will witness robust growth. Also, tie-ups the top medical institutes will grow in the upcoming years. The product variations and new drugs will lead to high growth prospects. Further, the market players will increase product range to meet demand from various sectors. All these growth factors of the market will lead to exceptional profitability of the monoclonal antibody therapy market. Also, the expansion rate is expected to be high in the monoclonal antibody therapy market. 

  • The market restraints 

The poor demand for monoclonal antibodies in undeveloped regions is a retaining factor. The awareness about antibody treatments is less in underdeveloped regions. The investments are the market low. Therefore, this can create a declining trend in the monoclonal antibody therapy market.

Further, the stringent government rules restrict the overall monoclonal antibody therapy market growth. The use of monoclonal antibody drugs requires plenty of compliance. The compliance standards delay the adoption of antibody drugs. The lack of demand from major undeveloped regions can damage the revenue rates. The expansion rate of the market can become lower due to these factors. 

  • The market challenges 

The health sector is advancing at an exponential pace. These developments are leading to high growth in the monoclonal antibody therapy market. However, more development in the drug market can. Also, it can lead to many substitutes. The alternatives for antibody therapy are surging. This can affect the overall demand of the monoclonal antibody drug therapy market in the forecast period.

Also, monoclonal antibody therapy side effects can hamper growth. Further, genetically treatment is high in cost. Also, the monoclonal antibody therapy is a combination of replica cells. Targeting and eliminating harmful cells in the body is possible. This custom treatment is expensive. This leads to a declining trend in the monoclonal antibody therapy market. 

  • The cumulative growth analysis 

The monoclonal antibody therapy market growth rate is steady in the forecast period. Next-generation genetic sequencing leads to remarkable development in the market. However, poor demand in undeveloped regions cab restricts the market demand.

Also, the high cost of treatment is a drawback in the monoclonal antibody therapy market. The key players who are off the market are taking cost-cutting initiatives. The monoclonal antibody therapy is expected to be cost efficient and more accessible in upcoming years. Additionally, the extensive research programs will lead to new product launches in the monoclonal antibody therapy market. The drug pipeline is strong for monoclonal antibodies the leading to a tremendous growth rate. 

  • The value chain analysis 

The profitable regional player of the monoclonal antibody therapy market is North America. It is a region holding maximum shares of the monoclonal antibody therapy market. The prevalence of chronic disorders will contribute to the high demand for monoclonal antibody therapy. Also, antibody therapy is affordable in these regions.

Due to the cost-effectiveness, more cancer patients prefer this treatment. Governmental support makes this treatment affordable in North America. Through advanced technologies product is effortless, and treatment is cost-effective. The exceptional reimbursement policies in this developed market lead to a higher adoption rate. In the forecast period, these regions will record the highest demand rate for the monoclonal antibody therapy market. 

Segment overview 

By source 

  • Human 

  • Murine 

  • Humanized 

  • Chimeric 

By indication 

By end-users 

  • Research institutions 

  • Hospitals 

By region 

  • North America 

  • Europe 

  • Asia pacific 

  • Latin America 

Competitive landscape 

The competition in the monoclonal antibody therapy market is low in the forecast period. However, the new entry of key players can increase the competition. Also, expansion, acquisitions, partnerships, mergers and acquisitions are key strategies in the competitive landscape. Research and development will be massive for this market in upcoming years. 

Regional analysis 

North America will continue to dominate other markets. High demand and efficient market operations will lead to high growth. Low-cost treatments attract many patients to the market. Also, the prevalence of cancer drives immense demand for monoclonal antibody therapy.

The Asia Pacific is the next largest region with the highest shares. A high need for antibody therapy is essential in this region. The growth of ageing populations increases the chronic illness rates. This ultimately creates a positive impact on the monoclonal antibody therapy market. Also, Europe is an emerging key player with high scope. Investment, research and expansion rate is high in Europe. 

The key player of the monoclonal antibody therapy market is 

  1. Sigma-Aldrich Co. LLC

  2. Sanofi

  3. Pfizer Inc

  4. Novartis AG

  5. Merck Kae

  6. Johnson & Johnson

  7. GlaxoSmithKline Plc GlaxoSmithKline Plc

  8. GenScript,

  9. AbbVie Inc

  10. Amgen Inc

  11. Bayer AG

  12. Biogen Inc

  13. Bristol

  14. Myers Squibb Company

  15. Hoffmann-La Roche Ltd

Recent developments 

  1. The monoclonal key players are expanding their market by developing clinical drugs for covid 19. This development of the market is crucial in today’s market scenario.  

  1. The Latin American region has new developments in the machinal antibody therapy market. The awareness about the treatment is rising in this region. 

Report overview 

  1. Market overview highlights 

  2. Analysis based upon COVID 19

  3. Explanation upon the Market Dynamics

  4. Value chain analysis

  5. Market segmentation overview

  6. The regional analysis

  7. Competitive landscape analysis

  8. Recent Developments

Report Scope:

Report Attribute/Metric Details
  Market Size   USD 458.1 billion
  CAGR   2022-2030:12.8%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   source, application and end users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   AbbVie Inc., Amgen Inc., Bayer AG, Biogen Inc., Bristol – Myers Squibb Company, F. Hoffmann-La Roche Ltd., GenScript, GlaxoSmithKline Plc., Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi, Sigma-Aldrich Co.
  Key Market Opportunities   Joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments
  Key Market Drivers   technological advancement, macro economical and governing factors

Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

The monoclonal antibody therapy market is projected grow at 12.8% CAGR during the assessment period (2022-2030).

Amgen Inc., AbbVie Inc., Bayer AG, Bristol–Myers Squibb Company, Biogen Inc., GenScript, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Merck KGaA, Johnson & Johnson, Novartis AG, Sanofi, Pfizer Inc., and Sigma-Aldrich Co. LLC, are some of the major players operating in the monoclonal antibody therapy market.

The Recombinant segment holds the largest share in the global monoclonal antibody therapy market.

North America holds the largest share in the global monoclonal antibody therapy market, followed by Europe and the Asia Pacific, respectively.

The valuation of the monoclonal antibody therapy market is estimated to increase to USD 458.1 billion by the end of 2030.